FDA Prop 65 NRT Warning Rejection Should Be Given Deference, Firms Say

FDA's view that a Prop 65 pregnancy warning on OTC nicotine replacement therapies is "without scientific foundation" should be given more weight, NRT firms assert in a brief filed in California Supreme Court Jan. 21